Skip to content
Screener

BioCryst Pharmaceuticals BCRX Debt-to-equity

Discontinued — last reported Q3 '20

Debt-to-equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.6×-0.7×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
0×0.0×
Precigen logo
PrecigenPGEN
4.9×—
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
3.7×—
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
0×-0.5×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.1×0.0×

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Return on equity-882.8%—
Current ratio2.3×+0.1×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

total debt/total stockholders equity=0.1×

Based on the most recent quarter.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed November 6, 2020. Open the filing →

Filed
Nov 6, 2020, 4:25 PM EST
Fiscal quarter
Q3 FY2020
Calendar quarter
Q3 2020
Accession
0001171843-20-007740

FAQ

What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.